Zacks: Brokerages Anticipate Atreca, Inc. (NASDAQ:BCEL) Will Post Earnings of -$0.78 Per Share

Wall Street brokerages expect Atreca, Inc. (NASDAQ:BCELGet Rating) to post earnings per share of ($0.78) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Atreca’s earnings, with the lowest EPS estimate coming in at ($0.82) and the highest estimate coming in at ($0.72). Atreca posted earnings per share of ($0.70) in the same quarter last year, which would suggest a negative year over year growth rate of 11.4%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Atreca will report full year earnings of ($3.07) per share for the current financial year, with EPS estimates ranging from ($3.39) to ($2.85). For the next year, analysts anticipate that the firm will report earnings of ($2.75) per share, with EPS estimates ranging from ($3.73) to ($2.37). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Atreca.

Atreca (NASDAQ:BCELGet Rating) last issued its quarterly earnings data on Thursday, March 3rd. The company reported ($0.79) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.04). During the same quarter in the prior year, the company earned ($0.63) EPS.

Several equities analysts have recently weighed in on BCEL shares. Stifel Nicolaus dropped their price objective on shares of Atreca from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, March 4th. Zacks Investment Research lowered shares of Atreca from a “buy” rating to a “hold” rating in a research report on Tuesday, March 8th. Wedbush restated an “outperform” rating on shares of Atreca in a research note on Friday, March 4th. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Atreca in a research note on Wednesday, April 6th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $16.65.

Shares of BCEL opened at $1.96 on Friday. The company has a 50-day moving average of $2.78. Atreca has a fifty-two week low of $1.56 and a fifty-two week high of $12.09.

In related news, insider Tito Serafini sold 30,000 shares of the company’s stock in a transaction dated Friday, March 4th. The shares were sold at an average price of $5.00, for a total value of $150,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 7.68% of the company’s stock.

A number of institutional investors have recently made changes to their positions in BCEL. BNP Paribas Arbitrage SA grew its stake in Atreca by 62.8% during the third quarter. BNP Paribas Arbitrage SA now owns 5,186 shares of the company’s stock worth $32,000 after buying an additional 2,000 shares in the last quarter. Virtu Financial LLC acquired a new stake in Atreca during the fourth quarter worth about $40,000. McDonald Partners LLC acquired a new stake in Atreca during the first quarter worth about $42,000. Gofen & Glossberg LLC IL acquired a new stake in Atreca during the first quarter worth about $48,000. Finally, Stifel Financial Corp grew its stake in Atreca by 48.8% during the fourth quarter. Stifel Financial Corp now owns 19,718 shares of the company’s stock worth $60,000 after buying an additional 6,463 shares in the last quarter. Hedge funds and other institutional investors own 57.48% of the company’s stock.

Atreca Company Profile (Get Rating)

Atreca, Inc, a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

See Also

Get a free copy of the Zacks research report on Atreca (BCEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atreca (NASDAQ:BCEL)

Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.